Clinical data
Other namesDetrifluoromethylfluoxetine
ATC code
  • None
  • N-Methyl-3-phenoxy-3-phenyl-1-propanamine
Chemical and physical data
Molar mass241.334 g·mol−1
3D model (JSmol)
  • CNCCC(Oc1ccccc1)c2ccccc2
  • InChI=1S/C16H19NO/c1-17-13-12-16(14-8-4-2-5-9-14)18-15-10-6-3-7-11-15/h2-11,16-17H,12-13H2,1H3

N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.[1][2][3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.[1][2][3]

See also


  1. ^ a b Francisco Lopez-Munoz; Cecilio Alamo (9 September 2011). Neurobiology of Depression. CRC Press. pp. 132–. ISBN 978-1-4398-3850-1.
  2. ^ a b Walter Sneader (31 October 2005). Drug Discovery: A History. John Wiley & Sons. pp. 416–417. ISBN 978-0-470-01552-0.
  3. ^ a b Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication". Life Sci. 57 (5): 411–41. doi:10.1016/0024-3205(95)00209-o. PMID 7623609.